Skip to main content

ANI Pharmaceuticals Inc

corporate_fare Company Profile

ANI Pharmaceuticals Inc

ANIP·NASDAQ·Life Sciences·CIK 0001023024

ANI Pharmaceuticals is a diversified bio-pharmaceutical company that develops, manufactures, and commercializes therapeutics through its Rare Disease, Generics, and Brands businesses. On September 16, 2024, the company acquired Alimera Sciences, Inc., adding two new products: ILUVIEN® and YUTIQ®. In March 2025, the FDA approved an expanded label for ILUVIEN to include the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye (NIU-PS), in addition to its existing indication for Diabetic Macular Edema (DME). The company is currently marketing ILUVIEN for both indications in the U.S. ILUVIEN was already approved for both DME and NIU-PS outside the U.S., including in seventeen European countries. During the second quarter of 2025, the company shifted its U.S. promotional efforts from YUTIQ to ILUVIEN, leveraging its combined label for DME and NIU-PS. The company owns and operates three pharmaceutical manufacturing facilities: two in Baudette, Minnesota, and one in East Windsor, New Jersey. These facilities are capable of producing oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products requiring a fully-contained manufacturing environment. The company ceased operations at a manufacturing facility in Oakville, Ontario, as of March 31, 2023.

ANI Pharmaceuticals Inc (NASDAQ:ANIP) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 27 items for ANIP at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • ANI Pharmaceuticals Reports Strong 2025 Financial Turnaround, Doubles Authorized Shares
  • ANI Pharmaceuticals Reports Record 2025 Results, Reaffirms Strong 2026 Guidance Driven by Rare Disease Growth
  • ANI Pharmaceuticals Backs 2026 Rev $1.055B-$1.115B >ANIP
  • ANI Pharmaceuticals Backs 2026 Adj EPS $8.83-Adj EPS $9.34 >ANIP
  • BRIEF-ANI Pharmaceuticals Q4 Adjusted EPS USD 2.33 Vs. IBES Estimate USD 2

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$883.37M
Net Income
$78.34M
Diluted EPS
$3.32
Op. Cash Flow
$185.22M
Free Cash Flow
$171.39M
Operating Income
$111.09M
Cash & Equivalents
$285.58M
Total Debt
$309.11M
Debt / Equity
0.57×
Net Margin
8.9%
Shares Outstanding
22.49M sh
Source: 10-K · filed 2026-02-27 · accession 0001023024-26-000014
$68.55
52-week range · as of 2026-11-05 $68.55 – $95.57
Market cap
$1.56B
Volume
227.3K (0.5× avg)
3-mo avg 428.9K
Live data · 2026-11-21 18:26 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed ANIP - Filings & News (Page 2)

ANIP
Feb 27, 2026, 6:59 AM EST
Filing Type: 10-K
Importance Score:
8
Price at Filing: $79.59
Real-time Price: $68.55 info
Change: -$11.04 (-14%) info
Market Cap: $1.558B info
ANIP
Feb 27, 2026, 6:57 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $79.59
Real-time Price: $68.55 info
Change: -$11.04 (-14%) info
Market Cap: $1.558B info
ANIP
Feb 27, 2026, 6:51 AM EST
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $78.79
Real-time Price: $68.55 info
Change: -$10.24 (-13%) info
Market Cap: $1.558B info
ANIP
Feb 27, 2026, 6:51 AM EST
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $79.59
Real-time Price: $68.55 info
Change: -$11.04 (-14%) info
Market Cap: $1.558B info
ANIP
Feb 27, 2026, 6:50 AM EST
Source: Reuters
Importance Score:
8
Price at Filing: $78.79
Real-time Price: $68.55 info
Change: -$10.24 (-13%) info
Market Cap: $1.558B info
ANIP
Feb 27, 2026, 6:50 AM EST
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $79.59
Real-time Price: $68.55 info
Change: -$11.04 (-14%) info
Market Cap: $1.558B info
ANIP
Jan 12, 2026, 4:15 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $84.35
Real-time Price: $68.55 info
Change: -$15.80 (-19%) info
Market Cap: $1.558B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets